CO2021010786A2 - Toxinas apxia, apxiia y apxiiia inactivadas - Google Patents

Toxinas apxia, apxiia y apxiiia inactivadas

Info

Publication number
CO2021010786A2
CO2021010786A2 CONC2021/0010786A CO2021010786A CO2021010786A2 CO 2021010786 A2 CO2021010786 A2 CO 2021010786A2 CO 2021010786 A CO2021010786 A CO 2021010786A CO 2021010786 A2 CO2021010786 A2 CO 2021010786A2
Authority
CO
Colombia
Prior art keywords
toxins
inactivated
apxiiia
apxia
apxiia
Prior art date
Application number
CONC2021/0010786A
Other languages
English (en)
Inventor
Volker Florian
Heiko Pidde
Sebastian Stentzel
Fabian Deutskens
Original Assignee
Ceva Sante Animale S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceva Sante Animale S A filed Critical Ceva Sante Animale S A
Publication of CO2021010786A2 publication Critical patent/CO2021010786A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen toxinas ApxIA, ApxIIA y ApxIIIA inactivadas, vacunas que comprenden dichas toxinas inactivadas y el uso de las mismas para la inmunización y protección de mamíferos.
CONC2021/0010786A 2019-01-30 2021-08-17 Toxinas apxia, apxiia y apxiiia inactivadas CO2021010786A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19154466.7A EP3689373A1 (en) 2019-01-30 2019-01-30 Inactivated apxia, apxiia and apxiiia toxins
PCT/EP2020/052334 WO2020157222A1 (en) 2019-01-30 2020-01-30 Inactivated apxia, apxiia and apxiiia toxins

Publications (1)

Publication Number Publication Date
CO2021010786A2 true CO2021010786A2 (es) 2021-10-29

Family

ID=65443641

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0010786A CO2021010786A2 (es) 2019-01-30 2021-08-17 Toxinas apxia, apxiia y apxiiia inactivadas

Country Status (8)

Country Link
EP (2) EP3689373A1 (es)
JP (1) JP2022519204A (es)
KR (1) KR20210141464A (es)
CN (1) CN113490506A (es)
BR (1) BR112021014944A2 (es)
CO (1) CO2021010786A2 (es)
MX (1) MX2021009105A (es)
WO (1) WO2020157222A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202011902D0 (en) * 2020-07-30 2020-09-16 Imperial College Innovations Ltd Antinobacillus pleuropneumoniae vaccines
CN112704732B (zh) * 2020-12-24 2022-02-25 华中农业大学 一种猪传染性胸膜肺炎放线杆菌亚单位疫苗
WO2022196816A1 (ja) * 2021-03-19 2022-09-22 国立大学法人三重大学 急性肺障害および肺線維症の急性増悪を改善するための医薬組成物
CN113416666A (zh) * 2021-04-27 2021-09-21 华中农业大学 猪胸膜肺炎放线杆菌血清10型突变菌株、ApxIA蛋白及应用
CN115960184B (zh) * 2022-09-28 2023-12-12 华中农业大学 一种溶血性曼氏杆菌a6血清型白细胞毒素抗原蛋白、其抗体及应用
CN117883560A (zh) * 2023-07-24 2024-04-16 华中农业大学 猪胸膜肺炎放线杆菌灭活亚单位联合疫苗及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69110082T2 (de) 1990-04-20 1995-11-09 Akzo Nobel Nv Untereinheit-Impfstoff gegen Actinobacillus Pleuropneumoniae.
US5994525A (en) * 1991-06-28 1999-11-30 Kamp; Elbarte Margriet Nucleic acid encoding Actinobacillus pleuropneumoniae cytolytic proteins
AUPN631495A0 (en) 1995-11-02 1995-11-23 Commonwealth Scientific And Industrial Research Organisation Vaccine and biological vector(I)
EP0810283A3 (en) 1996-05-31 1997-12-10 Akzo Nobel N.V. Live attenuated RTX-procucing bacteria of the family Pasteurellaceae
US6770275B1 (en) * 1996-05-31 2004-08-03 Akzo Nobel N.V. Live attenuated RTC-producing bacteria of the family
ES2233145B1 (es) 2002-11-20 2006-07-16 Laboratorios Hipra, S.A. Vacuna viva atenuada contra la pleuroneumonia porcina.
CN101265457B (zh) * 2007-07-20 2011-01-26 华中农业大学 区分疫苗免疫和野毒感染动物的猪胸膜肺炎放线杆菌血清7型双基因缺失突变株的疫苗及应用
ES2416154B1 (es) * 2011-11-09 2015-04-01 Laboratorios Hipra, S.A. Cepa viva atenuada de Actinobacillus pleuropneumoniae

Also Published As

Publication number Publication date
EP3897707A1 (en) 2021-10-27
EP3689373A1 (en) 2020-08-05
WO2020157222A8 (en) 2021-09-10
JP2022519204A (ja) 2022-03-22
KR20210141464A (ko) 2021-11-23
MX2021009105A (es) 2021-09-08
WO2020157222A1 (en) 2020-08-06
CN113490506A (zh) 2021-10-08
BR112021014944A2 (pt) 2021-11-09

Similar Documents

Publication Publication Date Title
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
BR112019012343A2 (pt) anticorpos il-11ra
CL2023001550A1 (es) Sistemas activos dinámicos acromosómicos.
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
CO2021004456A2 (es) Vacunas neumocócicas multivalentes
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
AR108468A1 (es) POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
BR112018014355A2 (pt) processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
ECSP21052193A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CL2023001140A1 (es) Formulaciones de anticuerpos anti-pd-l1
CO2022009737A2 (es) Anticuerpos anti-ly6g6d y métodos de uso
CL2020001856A1 (es) Métodos para tratar la enfermedad de farber.
CO2017010692A2 (es) Construcciones de calicheamicina y sus métodos de uso
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.
BR112018072592A2 (pt) vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos
BR112022009587A2 (pt) Anticorpo anti-pcsk9 e uso do mesmo
CL2021002501A1 (es) Compuestos novedosos y métodos de uso de los mismos.
BR112018010596A2 (pt) anticorpos para cgrp e usos dos mesmos